Literature DB >> 15081354

Path to equality strewn with roX.

Richard L Kelley1.   

Abstract

Male flies hypertranscribe most genes along their single X chromosome to match the output of females with two X chromosomes. This is mediated by chromatin modifications carried out by the MSL complex composed of noncoding roX RNA and at least five MSL proteins. New results indicate that one of these subunits, the MOF acetyltransferase, not only acts on histone H4, but on itself and MSL3. Cycles of covalent modifications of the MSL subunits may determine the proper level of hypertranscription or control cis spreading along the chromosome. The MSL complex binds to the roX genes, the very source of the RNA component of the complex. New details of how this interaction occurs hint at a possible autoregulatory function. Finally, despite intensive efforts, the molecular mechanism by which the MSL complex distinguishes the X from the autosomes remains a mystery. The MSL complex is able to spread epigenetically from the site of roX transcription, and recent work has defined the conditions that control local cis spreading. However, it is equally clear that soluble MSL complex can distinguish the X chromosome from autosomes. Reconciling all these findings into a unified model presents a challenge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081354     DOI: 10.1016/j.ydbio.2004.01.039

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  10 in total

Review 1.  Divergent actions of long noncoding RNAs on X-chromosome remodelling in mammals and Drosophila achieve the same end result: dosage compensation.

Authors:  Subhash C Lakhotia
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

2.  Nonrandom representation of sex-biased genes on chicken Z chromosome.

Authors:  R Storchová; P Divina
Journal:  J Mol Evol       Date:  2006-10-06       Impact factor: 2.395

3.  Chromodomain-mediated spreading on active genes.

Authors:  Alison M Hosey; Marjorie Brand
Journal:  Nat Struct Mol Biol       Date:  2009-01       Impact factor: 15.369

4.  Identification of putative noncoding polyadenylated transcripts in Drosophila melanogaster.

Authors:  Jonathan L Tupy; Adina M Bailey; Gina Dailey; Martha Evans-Holm; Christian W Siebel; Sima Misra; Susan E Celniker; Gerald M Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-04       Impact factor: 11.205

5.  A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16.

Authors:  Edwin R Smith; Christelle Cayrou; Rong Huang; William S Lane; Jacques Côté; John C Lucchesi
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

6.  Incorporation of the noncoding roX RNAs alters the chromatin-binding specificity of the Drosophila MSL1/MSL2 complex.

Authors:  Fang Li; Anja H Schiemann; Maxwell J Scott
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

Review 7.  Gene regulation and large-scale chromatin organization in the nucleus.

Authors:  Niall Dillon
Journal:  Chromosome Res       Date:  2006       Impact factor: 5.239

8.  Experimental RNomics and genomic comparative analysis reveal a large group of species-specific small non-message RNAs in the silkworm Bombyx mori.

Authors:  Dandan Li; Yanhong Wang; Kun Zhang; Zhujin Jiao; Xiaopeng Zhu; Geir Skogerboe; Xiangqian Guo; Viswanathan Chinnusamy; Lijun Bi; Yongping Huang; Shuanglin Dong; Runsheng Chen; Yunchao Kan
Journal:  Nucleic Acids Res       Date:  2011-01-11       Impact factor: 16.971

9.  Requirement of male-specific dosage compensation in Drosophila females--implications of early X chromosome gene expression.

Authors:  Natalie Gladstein; Meghan N McKeon; Jamila I Horabin
Journal:  PLoS Genet       Date:  2010-07-29       Impact factor: 5.917

10.  Targeting determinants of dosage compensation in Drosophila.

Authors:  Ina K Dahlsveen; Gregor D Gilfillan; Vladimir I Shelest; Rosemarie Lamm; Peter B Becker
Journal:  PLoS Genet       Date:  2006-02-03       Impact factor: 5.917

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.